Clinical Trials

An open-label randomised Phase 3 study of MK - 2870 by itself and in combination with Keytruda versus a treatment of physicians choice in participants with HR+/HER2- unresectable, locally advanced or metastatic breast cancer.
More details

The PAM study is designed to explore the effects of combining a talk therapy called meaning-centred psychotherapy with repeated microdoses (very small doses) of LSD on psychological well-being and cancer-related distress.
More details

This study will evaluate the safety and efficacy of targeted therapies or immunotherapy in participants with have inoperable tumours that have a genetic mutation.
More details

This trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.
More details

New Zealand Clinical Research is calling for male volunteers in Auckland and Christchurch to participate in two large trials looking at potential new treatments for breast cancer.
More details

The new clinical trial is recruiting from October 2024 in Auckland, Waikato, Bay of Plenty and Palmerston North. The trial aims to use a newly discovered radioactive tracer called Fibroblast Activation Protein Inhibitor (FAPI) in CT imaging to accurately diagnose and stage lobular breast cancers. People with lobular breast cancer are encouraged to speak to their medical team about eligibility.
More details

The New Zealand Familial Breast Cancer Study commenced in 2013 with the key goal of better-understanding DNA sequence changes in genes that alter the risk of developing breast cancer
More details

This is an observational cohort study of toxicity in female patients treated for early breast cancer with Adriamycin and Cyclophosphamide chemotherapy.
More details

A phase one clinical study to test safety and how well the oral drug ZN-A-1041 works by itself, or with another approved drug (PHESGO of Enhertu). As this is a phase one study, the sponsor will also be looking at how well ZN-A-1041 is tolerated and how it interacts within the body.
More details

This study looks at using a magnetic tracer verses a standard technique for sentinel node biopsy in breast cancer.
More details

BRCA-P is an international breast cancer prevention clinical trial open to women with a confirmed BRCA1 gene mutation who have not had a diagnosis of breast cancer.
More details

This trial will investigate if treatment with a PI3K inhibitor (alpelisib), in combination with fulvestrant, will improve outcomes for patients with metastatic breast cancer when compared with standard treatment.
More details

Lifepool is a research resource for study into breast cancer and women's health. It aims to recruit 100,000 Australian women. This will establish one of the largest cohorts in the world, providing research tools to answer critical questions about breast cancer. Lifepool aims to gather information on health and lifestyle, mammogram data and asks permission to track the health of each participant through linkage with other health databases.
More details

This study will investigate the feasibility of using oestradiol vaginal tablets for women on adjuvant aromatase inhibitors for breast cancer.
More details

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer.
More details

This study will investigate whether delivering radiation therapy while patients are in a prone position can help minimise skin toxicities ahead of surgery.
More details

This trial is investigating the efficacy and feasibility of a personalised risk assessment for breast and ovarian cancer, through offering a polygenic risk score.
More details

An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
More details